International Journal of Immunology

Special Issue


  • Submission Deadline: 30 January 2015
  • Status: Submission Closed
  • Lead Guest Editor: Julius Oloke
About This Special Issue
The aim of this special issue titled " Immunotherapy" is to enhance effective health care delivery by giving researchers opportunity to share their recent findings in the stimulation of immune system .

Immunotherapy is the "treatment of disease by inducing, enhancing, or suppressing an immune response". Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapy

The active agents of immunotherapy are collectively called immunomodulators. They are diverse array of recombinants, synthetic and natural preparations, often cytokines. Some of these substances, such as granulocyte colony-stimulating factor, interferon, imiquimod and cellular membrane fractions from bacteria are already licensed for use in patens. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine oligodeoxynucleotides and glucans are currently been investigated in clinical and preclinical studies.

Immunomodulatory regimes offer an attractive approach as they often have fewer side effects than the existing drugs, including less potential for creating resistance in microbial disease. Immune effector cells such as lymphocytes, macrophages dendritic cells, natural killer cells, cytotoxic T lymphocytes work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of the tumor due to mutation.

For this special issue; researchers are encouraged to send in their manuscripts covering the following topics:

1. Autologous immune enhancement therapies
2. Vaccination
3. Cancer immunotherapy
4. Immunosuppressive drugs
5. Allergen immunotherapy
6. Helminthic therapies
7. Genetically engineered T cells
8. T cell adoptive transfer
9. Dendritic cell-based immunotherapy
Lead Guest Editor
  • Julius Oloke

    Department of Microbiology and Immunology, All Saint University, St. Vincent and the Grenadines

Guest Editors
  • Sunny Kumar

    University of California Santa Barbara (UCSB), Santa Barbara, CA, United States

  • Preety Sahdev

    Allergan Inc, Pharmaceutical Sciences, Irvine, United States

Published Articles
  • Effectiveness of Immunotherapies from Oyster Mushroom (Pleurotus species) in the Management of Immunocompromised Patients

    Oloke J. K. , Adebayo E. A.

    Issue: Volume 3, Issue 2-1, March 2015
    Pages: 8-20
    Received: 14 January 2015
    Accepted: 19 January 2015
    Published: 7 February 2015
    DOI: 10.11648/j.iji.s.2015030201.12
    Abstract: In the recent years, mushrooms are distinguished as important natural resources of immunotherapy which can be used as immunomodulating and immunostimulating in the management of some immunodeficiency diseases such as cancer, tumour, HIV, tuberculosis etc. Mushroom of the genus Pleurotus are good sources of several bioactive compounds which are able... Show More
  • Challenges of the Control of Opportunistic Infections of Zoonotic Origin in HIV/AIDS Patients

    Yemisi Olukemi Adesiji , Julius Kola Oloke

    Issue: Volume 3, Issue 2-1, March 2015
    Pages: 1-7
    Received: 14 January 2015
    Accepted: 19 January 2015
    Published: 7 February 2015
    DOI: 10.11648/j.iji.s.2015030201.11
    Abstract: The HIV/AIDS pandemic is associated with a number of opportunistic infections of immunocompromised person. Some of these infections are recognized zoonoses that are naturally transmitted between animals and humans. These may be directly transmitted by, animals or indirectly by contact with contaminated food and water. Interactions between animals a... Show More